ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropin) in Adults With Growth Hormone Deficiency.

ClinicalTrials.gov ID: NCT02229851

Public ClinicalTrials.gov record NCT02229851. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 17, 2026, 6:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicentre, Multinational, Randomised, Parallel-group, Placebo-controlled (Double Blind) and Active-controlled (Open) Trial to Compare the Efficacy and Safety of Once Weekly Dosing of NNC0195-0092 (Somapacitan) With Once Weekly Dosing of Placebo and Daily Norditropin® FlexPro® in Adults With Growth Hormone Deficiency for 35 Weeks, Followed by a 53-week Open-label Extension Period

Study identification

NCT ID
NCT02229851
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novo Nordisk A/S
Industry
Enrollment
301 participants

Conditions and interventions

Interventions

  • placebo Drug
  • somapacitan Drug
  • somatropin Drug

Drug

Eligibility (public fields only)

Age range
23 Years to 79 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 30, 2014
Primary completion
Apr 20, 2017
Completion
May 6, 2018
Last update posted
Nov 22, 2020

2014 – 2018

United States locations

U.S. sites
29
U.S. states
18
U.S. cities
26
Facility City State ZIP Site status
Novo Nordisk Investigational Site Birmingham Alabama 35233
Novo Nordisk Investigational Site Los Angeles California 90033
Novo Nordisk Investigational Site Los Angeles California 90095
Novo Nordisk Investigational Site Aurora Colorado 80045
Novo Nordisk Investigational Site Atlanta Georgia 30318
Novo Nordisk Investigational Site Roswell Georgia 30076
Novo Nordisk Investigational Site Topeka Kansas 66606
Novo Nordisk Investigational Site Baltimore Maryland 21205
Novo Nordisk Investigational Site Boston Massachusetts 02114
Novo Nordisk Investigational Site East Lansing Michigan 48824
Novo Nordisk Investigational Site St Louis Missouri 63110
Novo Nordisk Investigational Site Omaha Nebraska 68105
Novo Nordisk Investigational Site Omaha Nebraska 68198-4120
Novo Nordisk Investigational Site Las Vegas Nevada 89128
Novo Nordisk Investigational Site Reno Nevada 89511
Novo Nordisk Investigational Site New York New York 10032
Novo Nordisk Investigational Site Cleveland Ohio 44195
Novo Nordisk Investigational Site Portland Oregon 97239
Novo Nordisk Investigational Site Philadelphia Pennsylvania 19104
Novo Nordisk Investigational Site Philadelphia Pennsylvania 19107
Novo Nordisk Investigational Site Pittsburgh Pennsylvania 15212
Novo Nordisk Investigational Site El Paso Texas 79935
Novo Nordisk Investigational Site Houston Texas 77030
Novo Nordisk Investigational Site Plano Texas 75093
Novo Nordisk Investigational Site San Antonio Texas 78229
Novo Nordisk Investigational Site Shavano Park Texas 78231
Novo Nordisk Investigational Site Salt Lake City Utah 84103
Novo Nordisk Investigational Site Federal Way Washington 98003
Novo Nordisk Investigational Site Seattle Washington 98122-5789

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 88 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02229851, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 22, 2020 · Synced May 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02229851 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →